Vitality Biopharma (OTCQB:VBIO) CEO Robert Brooke tells Proactive Investors about the company’s development of cannabinoid prodrug pharmaceuticals and how cannabinoids can be used for the treatment of serious neurological and inflammatory disorders.
Brooke says the cannabinoid prodrugs (known as cannabosides) can, upon ingestion, enable selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. This could be used by people with conditions such as Crohn’s, IBS and colitis.
Brooke says cannabinoids also have the potential to be used as an alternative to opiate abuse.
View original source video by clicking here